Release Date
Geography
Language of Resource
Full Text Available
Open Access / OK to Reproduce
Peer Reviewed
Objective
We developed a survey to assess clinician self-reported barriers, perceptions, and practices for treating HCV-infected patients with SUD and the associations of these barriers, perceptions, and practices with the willingness of clinicians to prescribe direct-acting antiviral (DAA) treatment for patients with HCV and substance use disorder (SUD) .
Findings/Key points
Findings from this survey study indicated that clinicians engaging in HCV care perceived patient-related barriers (e.g., failure to keep appointments) and prior authorization requirements to be significant problematic barriers to treating patients with HCV and SUD. The findings also underscore the importance of clinicians’ beliefs and comfort levels toward patients with HCV and SUD in the reported likelihood of prescribing DAAs. Despite such challenges, this study highlighted the willingness of HCV clinicians to provide DAA treatment to current or former PWID infected with HCV. Multidimensional strategies providing regularly updated education regarding SUDs to health care professionals offering HCV care and adoption of multidisciplinary teams with case management services coupled with less restrictive prior authorization requirements would enhance treatment access among PWID.
Design/methods
Survey (n=96)
